This HTML5 document contains 54 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n18http://localhost/temp/predkladatel/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n5http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n16http://bibframe.org/vocab/
n12http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216224%3A14110%2F14%3A00075704%21RIV15-MSM-14110___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216224%3A14110%2F14%3A00075704%21RIV15-MSM-14110___
rdf:type
n5:Vysledek skos:Concept
dcterms:description
Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods: A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis. Results: No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods: A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the present analysis. Results: No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281).
dcterms:title
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
skos:prefLabel
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
skos:notation
RIV/00216224:14110/14:00075704!RIV15-MSM-14110___
n3:aktivita
n4:I n4:N
n3:aktivity
I, N
n3:cisloPeriodika
%22article number%22 323
n3:dodaniDat
n13:2015
n3:domaciTvurceVysledku
n14:1559729 n14:9067094 n14:4504135
n3:druhVysledku
n6:J
n3:duvernostUdaju
n17:S
n3:entitaPredkladatele
n12:predkladatel
n3:idSjednocenehoVysledku
5135
n3:idVysledku
RIV/00216224:14110/14:00075704
n3:jazykVysledku
n10:eng
n3:klicovaSlova
Colorectal cancer; Bevacizumab; Capecitabine; 5-fluorouracil; Oxaliplatin
n3:klicoveSlovo
n7:Capecitabine n7:Bevacizumab n7:5-fluorouracil n7:Oxaliplatin n7:Colorectal%20cancer
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[CFBFAF626712]
n3:nazevZdroje
BMC CANCER
n3:obor
n11:FD
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
12
n3:rokUplatneniVysledku
n13:2014
n3:svazekPeriodika
14
n3:tvurceVysledku
Pavlík, Tomáš Dušek, Ladislav Buchler, Tomáš Abrahamova, Jitka Melichar, Bohuslav Obermannova, Radka Vyzula, Rostislav Usiaková, Zuzana Benesova, Vera Bortlíček, Zbyněk Kiss, Igor Kohoutek, Milan
n3:wos
000336688900002
s:issn
1471-2407
s:numberOfPages
7
n16:doi
10.1186/1471-2407-14-323
n18:organizacniJednotka
14110